Partnerships for the Development of Universal Influenza Vaccines (R21/R33 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-20-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support development of promising universal influenza vaccine candidates that protect against both influenza A and B viruses. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 27, 2020 Category: Research Source Type: funding
Rational Design of Vaccines Against Hepatitis C Virus (U19 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-20-019 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support novel strategies for the rational design of vaccines against hepatitis C virus (HCV), to assess the vaccines for their ability to induce protective immune responses, and to select candidates for preclinical development and clinical testing. To this end, it will be critical to advance knowledge of the structural basis for broad immunological protection, and to elucidate correlates of HCV protection by leveraging samples from existing human cohorts and vaccine studies. Thi...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 24, 2020 Category: Research Source Type: funding
Vaccine and Treatment Evaluation Units (VTEUs): Enhancing Capability and Capacity (UM1 Clinical Trial Required)
Funding Opportunity RFA-AI-20-021 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to solicit applications for the Vaccine and Treatment Evaluation Units (VTEUs) to implement clinical site protocols (clinical research, clinical trials) for evaluating vaccines, other preventive biologics, therapeutics, diagnostics, including prognostic and predictive markers, and devices for the treatment and prevention of infectious diseases as part of NIAID Infectious Diseases Clinical Research Consortium (IDCRC). A companion FOA solicits applications for the Leadership Group for the ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 19, 2020 Category: Research Source Type: funding
Molecular Mechanisms of Combination Adjuvants (MMCA) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-20-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications that propose studies of the mechanism of action of a combination of two or more vaccine adjuvants (combination adjuvant). Adjuvants that are combined in these studies must already have shown individual immune modulating activity. Understanding the molecular and cellular mechanisms underlying the synergistic enhancement of immune responses by combination adjuvants will facilitate the rational selection of components for vaccines tailored to specific pathogens. The Cooperative Ag...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 6, 2020 Category: Research Source Type: funding
Notice of NHLBI Participation in PAR-19-307, "Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)"
Notice NOT-HL-19-745 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 19, 2019 Category: Research Source Type: funding
Notice of Special Interest (NOSI): Development of Nucleic Acid-based Vaccines Against Seasonal and/or Pandemic Influenza
Notice NOT-AI-20-017 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 16, 2019 Category: Research Source Type: funding
NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-072 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs may address scientific areas relevant to the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function system development and function; and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 9, 2019 Category: Research Source Type: funding
NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
Funding Opportunity PAR-20-063 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institute of Allergy and Infectious Diseases (NIAID), invites applications for investigator-initiated Resource-Related Research Projects (R24). The proposed resource must provide a significant benefit to currently funded high priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID. It is anticipated that the ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 22, 2019 Category: Research Source Type: funding
Clarification of Research Areas for NIAID RFA-AI-19-059: Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed)
Notice NOT-AI-20-006 from the NIH Guide for Grants and Contracts (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 30, 2019 Category: Research Source Type: funding
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-AI-19-059 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate basic research, discovery, and early translational research to enable and accelerate the generation of highly efficacious pre-erythrocytic stage, sporozoite-based vaccines. Cross-fertilization and collaboration among investigators from malaria vaccine research and other basic research areas such as parasite biology, parasite genomics, pathogenesis, and host immunology are highly encouraged. The goal is to generate one or more promising vaccine candidates against human malaria that exhibit perform...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 11, 2019 Category: Research Source Type: funding
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional)
Funding Opportunity PAR-19-358 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare de...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 29, 2019 Category: Research Source Type: funding
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional)
Funding Opportunity PAR-19-359 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare de...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 29, 2019 Category: Research Source Type: funding
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional)
Funding Opportunity PAR-19-360 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare de...
Source: NIH Funding Opportunities (Notices, PA, RFA) - August 29, 2019 Category: Research Source Type: funding
Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and/or Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01 Clinical Trial Not Allowed)
Funding Opportunity PAR-19-307 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or progression to active tuberculosis (TB) disease. Such responses may be operative in mycobacterial infection, or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected and/or uninfected individuals. Research supp...
Source: NIH Funding Opportunities (Notices, PA, RFA) - June 28, 2019 Category: Research Source Type: funding
Conference for Early Stage HIV/AIDS Researchers Using Nonhuman Primate Models (R13 Clinical Trial Not Allowed)
The objectives of the meeting(s) supported by this FOA are to provide these early stage HIV/AIDS researchers with guidance on conducting preclinical research to inform clinical trials on reducing the incidence of HIV/AIDS infection, including vaccine development and testing; developing next-generation HIV therapies, including potential cure therapies; treatment of HIV-associated coinfections, comorbidities and complications; and infection prevention strategies. In addition to guidance on translating results to clinical trials, the conference should target developing skills related to networking, grantsmanship, and goal/mil...
Source: NIH Funding Opportunities (Notices, PA, RFA) - May 3, 2019 Category: Research Source Type: funding
